Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 4:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,891 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: insulin human Clear all
Recruiting Not applicable Interventional Accepts healthy volunteers

Breaking up Prolonged Sedentary Behavior to Improve Cardiometabolic Health

NCT05353322
View directory record Official record
Conditions
Sedentary Behavior, Cardiometabolic Risk Factors, Blood Pressure, Glucose
Interventions
Sedentary Break (Walking) Condition, Sitting (Control) Condition, Controlled Diet
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
324 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Sep 9, 2026, 4:13 PM EDT
Completed Phase 3 Interventional

Cystic Fibrosis - Insulin Deficiency, Early Action

NCT01100892
View directory record Official record
Conditions
Cystic Fibrosis, Diabetes
Interventions
Once-daily insulin detemir
Drug
Lead sponsor
Sydney Children's Hospitals Network
Other
Eligibility
5 Years to 19 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2023
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 30, 2023 · Synced Sep 9, 2026, 4:13 PM EDT
Completed No phase listed Observational

Prospective Observation Study of Insulin Sensitivity During and After Gonadotropin Releasing Hormone Agonist Therapy for Prostate Cancer

NCT00456144
View directory record Official record
Conditions
Prostate Cancer
Interventions
Gonadotropin Releasing Hormone Agonist Therapy
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Male only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 10, 2013 · Synced Sep 9, 2026, 4:13 PM EDT
Completed No phase listed Observational

Assessment of Insulin Production From Native Pancreas in Patients With Pancreas Transplants

NCT00246844
View directory record Official record
Conditions
Long-Functioning Pancreas Allografts, Pancreas Transplant
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 9, 2026, 4:13 PM EDT
Completed Not applicable Interventional Results available

Fully Automated Closed Loop Control in Adolescents With Type 1 Diabetes

NCT04545567
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
RocketAP, USS Virginia
Device
Lead sponsor
University of Virginia
Other
Eligibility
12 Years to 25 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 19, 2022 · Synced Sep 9, 2026, 4:13 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of ORMD-0801 (Oral Insulin) in Patients With Type 2 Diabetes Mellitus

NCT03467932
View directory record Official record
Conditions
T2DM (Type 2 Diabetes Mellitus)
Interventions
Cohort A: ORMD-0801, Placebo oral capsule, Cohort B: ORMD-0801
Drug
Lead sponsor
Oramed, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
373 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Flint, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Sep 9, 2026, 4:13 PM EDT
Completed Phase 4 Interventional Results available

The Effect of Exenatide Compared to Lantus Insulin on Vascular Function in Type 2 Diabetes

NCT00353834
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Exenatide, Glargine Insulin
Drug
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
18 Years to 75 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 8, 2018 · Synced Sep 9, 2026, 4:13 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Mutations Associated With Parkinson s Disease

NCT01547832
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 80 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Sep 9, 2026, 4:13 PM EDT
Not listed Not applicable Interventional

The Usability, Acceptability, and Perceived Value of the Cornerstones4Care Powered by Glooko App

NCT03222284
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Cornerstones4Care Powered by Glooko App
Device
Lead sponsor
Healthcare Innovation Technology Lab
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced Sep 9, 2026, 4:13 PM EDT
Completed Phase 4 Interventional Results available

Randomized, Double Blind, 2 Way Crossover Study of CSII With, Versus Without, Pretreatment With Human Hyaluronidase

NCT01526733
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Sham Injection, Recombinant human hyaluronidase PH20, Insulin aspart, Insulin lispro
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Feb 25, 2019 · Synced Sep 9, 2026, 4:13 PM EDT
Completed Phase 4 Interventional Results available

Perioperative Insulin Glargine Dosing Study

NCT00309465
View directory record Official record
Conditions
Diabetes, Surgery
Interventions
Lantus, Insulin
Drug · Other
Lead sponsor
Tamra Dukatz
Other
Eligibility
18 Years and older
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
2
States / cities
Royal Oak, Michigan • Troy, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 2, 2012 · Synced Sep 9, 2026, 4:13 PM EDT
Completed No phase listed Observational

Exercise in Insulin-Resistant Minority Adolescents

NCT00345436
View directory record Official record
Conditions
Insulin-Resistance
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
14 Years to 18 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 9, 2026, 4:13 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Study to Determine the Effects of Human Growth Hormone and Pioglitazone in Overweight, Prediabetic Adults

NCT00352287
View directory record Official record
Conditions
Obesity, Metabolic Syndrome, Impaired Glucose Tolerance
Interventions
Recombinant human growth hormone; pioglitazone
Drug
Lead sponsor
Stanford University
Other
Eligibility
40 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2005
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jul 13, 2006 · Synced Sep 9, 2026, 4:13 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Sleep Timing on Energy Intake and Energy Expenditure

NCT05096585
View directory record Official record
Conditions
Obesity
Interventions
Delayed bedtime sleep restriction, Early wake sleep restriction
Behavioral
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
21 Years to 45 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 9, 2023 · Synced Sep 9, 2026, 4:13 PM EDT
Recruiting Not applicable Interventional

Wild Blueberries for Gut, Brain, and Cardiometabolic Health in Prediabetes

NCT06735651
View directory record Official record
Conditions
Prediabetes (Insulin Resistance, Impaired Glucose Tolerance), Female, Adult, Endothelial Function (Reactive Hyperemia), Arterial Stiffness, Cognition, Oxidative Stress, Gut Microbiota, Overweight, Inflammation, Microvascular Function, Body Composition
Interventions
Wild Blueberry, Placebo
Dietary Supplement
Lead sponsor
Georgia State University
Other
Eligibility
20 Years to 65 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 9, 2026, 4:13 PM EDT
Completed Phase 3 Interventional

Improving Neurologic Outcomes in People With Diabetes Who Are Undergoing Heart Surgery

NCT00836329
View directory record Official record
Conditions
Diabetes Mellitus, Cardiovascular Diseases
Interventions
Intensive Glucose Management, Traditional Glucose Management:
Behavioral
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
35 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 11, 2016 · Synced Sep 9, 2026, 4:13 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

The Fenofibrate and Metformin for Atherogenic Dyslipidemia (FAMA) Study

NCT00400231
View directory record Official record
Conditions
Metabolic Syndrome x
Interventions
Study drugs: Metformin and fenofibrate, Study Drug: Metformin, Study Drug: fenofibrate, Metformin and Fenofibrate placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 75 Years
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 19, 2017 · Synced Sep 9, 2026, 4:13 PM EDT
Completed Phase 3 Interventional Results available

A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification

NCT02100475
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec/liraglutide, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
7
States / cities
Fresno, California • Fort Lauderdale, Florida • Gurnee, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Sep 9, 2026, 4:13 PM EDT
Terminated Phase 1 Interventional

Effect of Cinnamon Extract on Insulin Resistance in Polycystic Ovary Syndrome

NCT00970541
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Insulin Resistance
Interventions
Cinnamon Supplementation, Placebo (wheat flour)
Dietary Supplement
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
20 Years to 40 Years · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Aug 24, 2021 · Synced Sep 9, 2026, 4:13 PM EDT
Terminated Phase 1 Interventional

A Phase 1 Study of [225Ac]-FPI-1434 Injection

NCT03746431
View directory record Official record
Conditions
Advanced Solid Tumours, Endometrial Cancer, Cervical Cancer, Ovarian Cancer, Breast Cancer, Triple Negative Breast Cancer (TNBC), HER2-negative Breast Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), Adrenocortical Carcinoma, Uveal Melanoma
Interventions
[111In]-FPI-1547 Injection, [225Ac]-FPI-1434 Injection multi-dose, FPI-1175 Infusion, [225Ac]-FPI-1434 Injection single-dose
Drug · Biological
Lead sponsor
Fusion Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
7
States / cities
Duarte, California • Boston, Massachusetts • Minneapolis, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Sep 9, 2026, 4:13 PM EDT
Completed Phase 3 Interventional Results available

A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus

NCT01952145
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec/liraglutide, insulin glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
557 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
31
States / cities
Fresno, California • Los Alamitos, California • Palm Springs, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2019 · Synced Sep 9, 2026, 4:13 PM EDT
Suspended Phase 1Phase 2 Interventional

Dose Safety Hybrid Closed Loop and Fully Automated Closed Loop Artificial Pancreas Device in CRC

NCT03428295
View directory record Official record
Conditions
Glucose, Low Blood, Glucose, High Blood
Interventions
Dose Safety AP system
Device
Lead sponsor
Dose Safety Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Redmond, Washington
Source: ClinicalTrials.gov public record
Updated Feb 11, 2019 · Synced Sep 9, 2026, 4:13 PM EDT
Completed Not applicable Interventional

The Effect of Intensive Insulin Therapy in the Surgical Critical Care Unit

NCT00282594
View directory record Official record
Conditions
Sepsis, Respiratory Failure, Renal Failure, Surgical Site Infection
Interventions
Novolin R (human recombinant Insulin)
Drug
Lead sponsor
Genesys
Other
Eligibility
18 Years and older
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Grand Blanc, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 26, 2006 · Synced Sep 9, 2026, 4:13 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Diet, Exercise and/or Rosiglitazone for HIV-Associated Insulin Resistance

NCT00264251
View directory record Official record
Conditions
HIV Infections, Insulin Resistance, Obesity
Interventions
Weight loss through diet and exercise, Rosiglitazone insulin sensitizing agent
Behavioral · Drug
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
20 Years to 60 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 28, 2007 · Synced Sep 9, 2026, 4:13 PM EDT